公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors | Takahashi S.; Karayama M.; Takahashi M.; Watanabe J.; Minami H.; Yamamoto N.; Kinoshita I.; CHIA-CHI LIN ; Im Y.-H.; Achiwa I.; Kamiyama E.; Okuda Y.; Lee C.; Bang Y.-J. | Clinical Cancer Research | 14 | 11 | |
2021 | Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer | Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU ; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. | Clinical Cancer Research | 14 | 10 | |
2022 | Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial | YEN-SHEN LU ; Im S.-A.; Colleoni M.; Franke F.; Bardia A.; Cardoso F.; Harbeck N.; Hurvitz S.; Chow L.; Sohn J.; Lee K.S.; Campos-Gomez S.; Vazquez R.V.; Jung K.H.; Babu K.G.; Wheatley-Price P.; De Laurentiis M.; Im Y.-H.; Kuemmel S.; El-Saghir N.; O'Regan R.; Gasch C.; Solovieff N.; Wang C.; Wang Y.; Chakravartty A.; Ji Y.; Tripathy D. | Clinical Cancer Research | 88 | 38 |